News | December 24, 2024
Ikena Oncology and Inmagene Biopharmaceuticals announce agreement for merger
The transaction is expected to result in approximately $175 million to support further development of IMG-007
The transaction is expected to result in approximately $175 million to support further development of IMG-007
It is developing the drug candidate to potentially treat immunological diseases
The planned Phase 1 study is a double-blind, randomized, placebo-controlled dose-escalation study in healthy adult subjects and AD patients
Subscribe To Our Newsletter & Stay Updated
